Last updated: February 27, 2026
What is the current market position of the drug with NDC 70677-1088?
The drug identified by NDC 70677-1088 is a branded biosimilar insulin glargine product marketed under the name Basaglar (also known as LY IG). It is a long-acting insulin used to treat diabetes mellitus type 1 and type 2. Released in 2016 by Lilly, Basaglar’s entrance into the market aimed to offer a less expensive alternative to incumbent insulin glargine products such as Sanofi’s Lantus.
Market share and competition:
In 2022, Basaglar held approximately 15% of the U.S. basal insulin market, primarily competing with Lantus (Sanofi) and newer biosimilars. The expansion of bios persecutions and further biosimilar entrants have increased market competition, exerting downward pressure on prices.
Prescription trends:
According to IQVIA data, basal insulin prescriptions in the U.S. increased at a compound annual growth rate (CAGR) of 2.5% from 2018 to 2022. Basal insulins dominate injectable anti-diabetes therapies, with total sales exceeding $7 billion in 2022.
Regulatory status:
Basaglar gained FDA approval for both new and follow-on biosimilar versions of insulin glargine in 2016. The drug is designated as a biosimilar, which influences its market dynamics via interchangeability and patent litigation.
How does the competitive landscape influence pricing?
The market features several insulin glargine formulations:
| Product |
Manufacturer |
Approximate 2022 Price (Wholesale Acquisition Cost, WAC) |
Market Share |
| Lantus |
Sanofi |
$174 per 10 mL |
~50% of basal insulin segment |
| Basaglar |
Lilly |
$148 per 10 mL |
15% of segment |
| Semglee (biosimilar, Mylan/Biocon) |
Mylan/Biocon |
$134 per 10 mL |
Growing presence |
| Basaglar |
Lilly |
$148 per 10 mL |
Same as above |
Prices for biosimilar insulins are generally 10-15% below originator prices. Patent litigation, legal challenges, and formulary preferences influence this pricing.
What are projections for future prices?
Factors influencing future prices:
- Patent litigation: Expirations of key patents, expected between 2024 and 2027, will open markets to additional biosimilars, intensifying competition.
- Manufacturing streamlining: Advances in biosimilar manufacturing reduce costs, potentially lowering prices further.
- Policy and legislation: CMS policies and Medicare Part D negotiations may impose price ceilings.
- Market acceptance: Prescriber and patient acceptance of biosimilars influence volume and, indirectly, price stabilization.
Projection overview:
| Year |
Estimated Average Wholesale Price (AWP) per 10 mL |
Price Change % |
Underlying Driver |
| 2023 |
$147 |
Baseline |
- |
| 2024 |
$144 |
-1.5% |
Patent cliff impacts |
| 2025 |
$140 |
-2.8% |
Increased biosimilar competition |
| 2026 |
$135 |
-3.6% |
Greater biosimilar market entries |
| 2027 |
$130 |
-3.7% |
Market saturation |
The decline in average prices reflects ongoing biosimilar market penetration and improved manufacturing efficiencies.
What risks could alter these projections?
- Patent extension strategies could delay biosimilar entry.
- Supply chain disruptions could temporarily suppress pricing.
- Regulatory changes could loosen or tighten biosimilar interchangeability standards.
- Pricing reforms through healthcare legislation could impose mandatory price reductions.
Final insights
The insulin glargine market is consolidating around biosimilar options. Prices are trending downward in response to increased market competition and patent expirations. By 2027, similar insulins could average prices below $130 per 10 mL, representing a 25–30% reduction from 2022 levels. Continued biosimilar entry and regulatory policies are primary drivers.
Key Takeaways
- NDC 70677-1088 (Basaglar) holds approximately 15% of the U.S. basal insulin market.
- Competitive pricing trends project a 3–4% annual decline in wholesale prices through 2027.
- Patent expirations between 2024 and 2027 will catalyze biosimilar market expansion.
- Price reductions will be impacted by regulatory policies and manufacturing innovations.
- Market share gains by biosimilars are likely to exert sustained downward pressure on insulin prices.
FAQs
-
When will the patents for Basaglar and similar insulins expire?
Major patents are expected to expire between 2024 and 2027, opening the market to more biosimilars.
-
How do biosimilar insulins impact the overall market?
They increase price competition, reduce average wholesale prices, and expand access.
-
Are biosimilar insulins interchangeable with originators in the U.S.?
Yes, under FDA approval standards, certain biosimilars are considered interchangeable; however, prescriber acceptance varies.
-
What is the primary driver of price declines?
Patent expirations and biosimilar market penetration.
-
Will pricing reforms affect insulin prices in the near term?
Possible, especially if legislation implements price caps or negotiating authority for federal programs.
References
[1] IQVIA. (2023). Prescription Data and Market Trends.
[2] U.S. Food and Drug Administration. (2022). Biosimilar Product Approval Reports.
[3] Centers for Medicare & Medicaid Services. (2023). Medicare Part D Formularies and Pricing.
[4] Statista. (2023). U.S. Insulin Market Volume and Revenue.
